Fixed-combination halobetasol propionate and tazarotene topical lotion decreases TNF-α and IL-17A levels in psoriatic lesions

References

• Grän F, Kerstan A, Serfling E, et al. Current developments in the immunology of psoriasis. Yale J Biol Med. 2020;93:1–6.
   Web of Science ®Google Scholar
• von Stebut E, Boehncke WH, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096. doi: 10.3389/fimmu.2019.03096.
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–2587. doi: 10.1084/jem.20060244.
   PubMed Web of Science ®Google Scholar
• Chima M, Lebwohl M. TNF inhibitors for psoriasis. Semin Cutan Med Surg. 2018;37(3):134–142. doi: 10.12788/j.sder.2018.039.
   PubMed Web of Science ®Google Scholar
• Yost J, Gudjonsson JE. The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep. 2009;1:30. doi: 10.3410/M1-30.
   PubMedGoogle Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi: 10.1007/s12016-018-8702-3.
   PubMed Web of Science ®Google Scholar
• Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350. doi: 10.1016/j.cyto.2014.12.014.
   PubMed Web of Science ®Google Scholar
• Kutwin M, Migdalska-Sęk M, Brzeziańska-Lasota E, et al. An analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R expression and their correlation with clinical course in patients with psoriasis. Journal of Clinical Medicine. 2021;10:5834. doi: 10.3390/jcm10245834.
   PubMed Web of Science ®Google Scholar
• Mohd Noor AA, Azlan M, Mohd Redzwan N. Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action. Biomedicines. 2022;10:498. doi: 10.3390/biomedicines10020498.
   PubMed Web of Science ®Google Scholar
• Immunex Corporation. Enbrel [package insert]. Thousand Oaks (CA): Immunex Corporation; 2022.
   Google Scholar
• Janssen Biotech I. Remicade [package insert]. Horsham (PA): Janssen Biotech I; 2021.
   Google Scholar
• AbbVie Inc. Humira [package insert]. North Chicago (IL): AbbVie Inc; 2021.
   Google Scholar
• Novartis Pharmaceuticals Corporation. Cosentyx [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2021.
   Google Scholar
• Eli Lilly and Company. Taltz [package insert]. Indianapolis (IN): Eli Lilly and Company; 2016.
   Google Scholar
• Bausch Health US L. Siliq [package insert]. Bridgewater (NJ): Bausch Health US L; 2017.
   Google Scholar
• Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19–40. doi: 10.1038/nrd.2018.183.
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Korman NJ, Prater EF, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432–470. doi: 10.1016/j.jaad.2020.07.087.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate-to-Severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17:855–861.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70–77. doi: 10.36849/JDD.2020.3977.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Stein Gold L, Del Rosso JQ, et al. Posttreatment maintenance of therapeutic effect with fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2022;33(4):2068–2074. doi: 10.1080/09546634.2021.1914310.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Tanghetti EA, Stein Gold L, et al. Fixed-combination halobetasol propionate and tazarotene in the treatment of psoriasis: narrative review of mechanisms of action and therapeutic benefits. Dermatol Ther (Heidelb). 2021;11(4):1157–1174. doi: 10.1007/s13555-021-00560-6.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Stein Gold L, Papp K, et al. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study. J Eur Acad Dermatol Venereol. 2021;35(5):1152–1160. doi: 10.1111/jdv.17113.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Cidlowski JA. Corticosteroids. Rheum Dis Clin North Am. 2016;42(1):15–31, vii. doi: 10.1016/j.rdc.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Issa N, Kircik L. Supplement individual article: a reappraisal of fixed-combination halobetasol propionate and tazarotene for the treatment of psoriasis: biological underpinnings, therapeutic mechanisms, and economic considerations. J Drugs Dermatol. 2023;22(1):3446174–34461710.
   PubMed Web of Science ®Google Scholar
• Pesce B, Ribeiro CH, Larrondo M, et al. TNF-α affects signature cytokines of Th1 and Th17 T cell subsets through differential actions on TNFR1 and TNFR2. Int J Mol Sci. 2022;23:9306.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Sun L, Jiang T, et al. TNFαPromotes Th17 cell differentiation through IL-6 and IL-1βProduced by monocytes in rheumatoid arthritis. J Immunol Res. 2014;2014:385352. doi: 10.1155/2014/385352.
   PubMed Web of Science ®Google Scholar
• Kircik L, Tanghetti EA, Friedman A, et al. Challenges in psoriatic disease addressed by Fixed-Combination halobetasol propionate 0.01% and tazarotene 0.045% lotion. J Clin Aesthet Dermatol. 2023;16:21–26.
   PubMedGoogle Scholar
• Ozyurekoglu E, Kircik L. An open-label pilot study to investigate safety and efficacy of fixed combination tazarotene 0.045% and halobetasol propionate 0.01% lotion for the treatment of scalp psoriasis. J Drugs Dermatol. 2021;20(11):1191–1194. doi: 10.36849/jdd.0102.
   PubMed Web of Science ®Google Scholar
• Campbell CR, Babalola FO, Yousif JE. 33385 A polymeric emulsion of halobetasol propionate and tazarotene in the treatment of palmoplantar psoriasis. Journal of the American Academy of Dermatology. 2022;87(3):AB10. doi: 10.1016/j.jaad.2022.06.075.
   Web of Science ®Google Scholar
• Steer JH, Kroeger KM, Abraham LJ, et al. Glucocorticoids suppress tumor necrosis factor-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-κB and c-Jun-Activating transcription factor-2 binding sites in the promoter. J Biol Chem. 2000;275(24):18432–18440. doi: 10.1074/jbc.M906304199.
   PubMed Web of Science ®Google Scholar